References
- Biomarkers and surrogate end points:preferred definitions and conceptual framework. Clin. Pharmacol Ther. 69, 89–95 (2001).
- Workman P, Clarke P Innovative cancerdrug targets: genomics, transcriptomics and clinomics. Expert Opin. Phalmacother. 2, 911–915 (2001).
- Wang SC, Zhang L, Hortobagyi GN,Hung MC. Targeting HER2: recent developments and future directions for breast cancer patients. Sernin. Oncol 28(6 Suppl. 18), 21–29 (2001).
- Scherf U, Ross D, Waltham M etal.A gene expression database for the molecular pharmacology of cancer. Natum Genet. 24,236–244 (2000).
- Pucci B, Kasten M, Giordano A. Cell cycleand apoptosis. Neoplasia 2,291–299 (2000).
- Anderson H, Price P, Blomley S etalMeasuring changes in human tumour vasculature in response to therapy using functional imaging techniques. BE j Cancer 85,1085–1093 (2001).